Pfizer Inc. (NYSE:PFE), one of the world's largest pharmaceutical companies with a market capitalization of $151.25 billion, finds itself at a critical juncture as it navigates the post-pandemic ...
Over the years, the U.S. Department of Justice (DOJ) has taken a host of drugmakers to task over alleged kickback payments ...
Following a tough opening salvo from Starboard Value last fall, Pfizer is getting a chance to catch its breath in the ...
In another cautionary tale of kicking all the tires before an acquisition, Pfizer Inc. agreed to a nearly $60 million settlement to resolve a whistleblower’s claims that Biohaven Pharmaceutical ...
Starboard last year took a $1 billion stake in Pfizer, looking to turn the pharma around after alleged severe shortcomings by ...
From Novo Holding's purchase of Catalent to BMS's Karuna acquisition, here are 10 of the most significant M&A moments of 2024 ...
Pfizer Inc. (NYSE:PFE) revealed results from the Phase 3 BREAKWATER trial evaluating Braftovi (encorafenib) in combination ...
Biohaven wielded meals at high-end restaurants and paid speaking opportunities to induce healthcare providers to prescribe ...
Pfizer (PFE), on behalf of its wholly-owned subsidiary Biohaven Pharmaceutical (BHVN), has agreed to pay $59,746,277 to resolve allegations ...
The alleged violations occurred before Pfizer bought Biohaven and its migraine treatment three years ago for $11.6 billion.
The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback